Jeet Mukherjee
ON THE RECORD · 4 verbatim quotes · every quote source-verified
“a mainstay of the future breast cancer treatment paradigm and other cancers.”
Jeet Mukherjee · said date not stated · reported 2026-10-24
Jeet Mukherjee says Faeth's regimen could become a mainstay of future breast cancer treatment and other cancers.
“are frequently preferred by patients,”
Jeet Mukherjee · said date not stated · reported 2026-10-24
Jeet Mukherjee notes that oral agents are frequently preferred by patients over injectables like Dupixent.
“has the potential to address safety and dosing limitations of another recently approved drug for breast cancer,”
Jeet Mukherjee · said date not stated · reported 2026-10-24
Jeet Mukherjee says Faeth Therapeutics' two-drug regimen could address safety and dosing limitations of a recently approved breast cancer drug.
“The drug has the potential to not only take share from patients taking Dupixent for numerous immunological diseases but also expanding the market to those not taking systemic biologic drugs,”
Jeet Mukherjee · said date not stated · reported 2026-10-24
Jeet Mukherjee tells CNBC that Kymera's oral drug could take share from Dupixent and expand the market to patients not taking systemic biologic drugs.